

**GENERAL CONFORMITY CERTIFICATE**  
**Consumer Protection Safety Improvements Act (CPSIA)**  
**15 U.S.C. § 2063(a)**

*The Manufacturer below certifies that the product identified below is in compliance with applicable CPSC-enforced safety rules.*

**1. Specific product covered by this certificate:**

OXALIPLATIN INJECTION (Eloxatin®)  
NDC # 00955-1727-20

**2. Specific regulation(s), rules, bans, and/or standards for which this product is being certified:**

16 CFR §§ 1700.14(a) & 1700.15

**3. Manufacturer or importer certifying compliance:**

Name: Sanofi US  
Mailing address: 55 Corporate Drive, Bridgewater, NJ 08807  
Telephone number: 1-800-372-6634

**4. Individual maintaining records of the test results upon which this certification is based:**

Name and/or title: Mark DeSieno  
Sr. Director, Industrial Development, Industrial Affairs  
55 Corporate Drive, Bridgewater, NJ 08807

For information contact:

Phone: 1-908-981-3922  
Email: [mark.desieno@sanofi.com](mailto:mark.desieno@sanofi.com)

**5. Date and place where this product was packaged:**

Products are packaged at one or more locations. For information on the date and place of packaging of a specific product, please contact us at 1-800-372-6634 or [TradeCustomerSupport@sanofi.com](mailto:TradeCustomerSupport@sanofi.com), with the Lot number and Expiration Date from the product container.

**6. Date and place where this product was tested for compliance and third party laboratory(ies) that conducted testing upon which this certification is based.**

Date of test reports: N/A

Name and Mailing Address of Testing Laboratory: N/A

If box is checked, then product testing requirements were not applicable



Approved: \_\_\_\_\_

*Mark DeSieno*

Date: \_\_\_\_\_

*20 Sept. 2018*

Sr. Director, Industrial Development, Industrial Affairs